Premium
Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program
Author(s) -
Keir Stephen T.,
Morton Christopher L.,
Wu Jianrong,
Kurmasheva Raushan T.,
Houghton Peter J.,
Smith Malcolm A.
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24016
Subject(s) - pazopanib , medicine , sarcoma , rhabdomyosarcoma , oncology , tyrosine kinase inhibitor , pharmacology , growth factor receptor , angiogenesis , soft tissue sarcoma , pediatric cancer , cancer , pathology , sunitinib
Pazopanib is an oral angiogenesis inhibitor targeting vascular growth factor receptor‐1, ‐2, and ‐3, platelet derived growth factor receptor‐α, platelet derived growth factor receptor‐β, and KIT that has demonstrated activity against a variety of adult cancer xenografts. Pazopanib was tested against a panel of pediatric rhabdomyosarcoma and Ewing sarcoma xenografts at a dose of 108 mg/kg/day or 100 mg/kg twice daily, administered orally for 28 days. While no objective responses were observed, pazopanib induced statistically significant differences in event‐free survival compared to controls in approximately one‐half of the sarcoma xenograft models tested. Though well tolerated, pazopanib showed limited activity against the sarcoma models evaluated, with the best tumor responses being growth delay. Pediatr Blood Cancer 2012;59:586–588. © 2011 Wiley Periodicals, Inc.